<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478568</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-058</org_study_id>
    <secondary_id>2008-000215-15</secondary_id>
    <nct_id>NCT01478568</nct_id>
  </id_info>
  <brief_title>To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together</brief_title>
  <official_title>An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of the CYP2D6 Substrate Desipramine in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate if blood levels of desipramine change whilst being dosed at the
      same time with daily mirabegron.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, one-sequence crossover design study to evaluate the drug-drug
      interaction between mirabegron and desipramine. The effect of mirabegron on the plasma
      concentration of desipramine will be evaluated after 13 day repeated administration. The
      recovery of CYP2D6 activity is also being explored by comparing the pharmacokinetic profiles
      of desipramine after a 2 week wash-out period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of desipramine assessed by plasma concentration while at steady state levels of mirabegron</measure>
    <time_frame>Pre-dose until 72 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monitoring of safety and tolerability through assessment of vital signs, ECG, clinical safety laboratory and adverse events</measure>
    <time_frame>Baseline until End of Study Visit (7 to 14 days after last dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of desipramine assessed by plasma concentration after wash-out of mirabegron</measure>
    <time_frame>Pre-dose until 72 hours after wash-out</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Pharmacokinetics of Mirabegron</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>mirabegron / desipramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirabegron</intervention_name>
    <description>oral</description>
    <arm_group_label>mirabegron / desipramine</arm_group_label>
    <other_name>YM178</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desipramine</intervention_name>
    <description>oral</description>
    <arm_group_label>mirabegron / desipramine</arm_group_label>
    <other_name>pertofrane</other_name>
    <other_name>norpramin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index between 18.5 and 30.0 kg/m2 inclusive

          -  Subject is genotyped and phenotyped as an extensive metabolizer for CYP2D6

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to YM178 or any of the components of the
             formulation used

          -  Known or suspected hypersensitivity to desipramine or any of the components of the
             formulation used

          -  Pregnant or breast feeding within 6 months before screening assessment

          -  Any clinical history of major depressive disorder, cardiovascular disease, urinary
             retention, glaucoma, thyroid disease and/or seizure disorder

          -  Any of the liver function tests (i.e. Alanine Aminotransferase (ALT), Asparate
             Aminotransferase (AST) and Alkaline phosphatase) above the upper limit of normal at
             repeated measurements

          -  Any clinically significant history of asthma, eczema, any other allergic condition or
             previous severe hypersensitivity to any drug (excluding non-active hay fever)

          -  Any clinically significant abnormality following the investigator's review of the
             pre-study physical examination, ECG and clinical laboratory tests

          -  Abnormal pulse rate and/or blood pressure measurements at the pre-study visit as
             follows: pulse rate &lt;40 or &gt;90 bpm; mean systolic blood pressure &gt;140 mmHg; mean
             diastolic blood pressure &gt;90 mmHg (blood pressure measurements taken in triplicate
             after subject has been resting in supine position for 5 min; pulse rate will be
             measured automatically)

          -  A marked baseline prolongation of QT/QTc interval after repeated measurements of &gt;450
             ms, a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias
             or torsades de pointes, structural heart disease, or a family history of Long QT
             Syndrome (LQTS)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Aster</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=638</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <reference>
    <citation>Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, Strabach G, van Gelderen M. The effect of mirabegron, a potent and selective Î²3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):43-52. doi: 10.1007/s13318-013-0133-1. Epub 2013 Jun 1.</citation>
    <PMID>23728524</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2011</study_first_submitted>
  <study_first_submitted_qc>November 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>Phase 1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
    <mesh_term>Desipramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

